Augmenting antitumor immune responses with epigenetic modifying agents.
about
Immune Mechanisms in Myelodysplastic SyndromeEpigenetic control of HIV-1 post integration latency: implications for therapyTargeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer ImmunityCombination Approaches with Immune-Checkpoint Blockade in Cancer TherapyThe Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cellsDNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire.Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical reviewHuman Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy.Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacyCombining Epigenetic and Immunotherapy to Combat Cancer.Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Digital analysis and epigenetic regulation of the signature of rejection in colorectal cancer.Hallmarks of response to immune checkpoint blockade.DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer.Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors.Editorial: Advances in Combination Tumor Immunotherapy.Histone deacetylase inhibitors as cancer therapeutics.New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade.Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice.Mechanisms of resistance to immune checkpoint inhibitors.Strategy to targeting the immune resistance and novel therapy in colorectal cancer.Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy.Decitabine Inhibits Gamma Delta T Cell Cytotoxicity by Promoting KIR2DL2/3 Expression.Mechanisms of Resistance to PD-1 and PD-L1 Blockade.The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer.Immune checkpoint therapy in liver cancer.Immunotherapy With Human Gamma Delta T Cells-Synergistic Potential of Epigenetic Drugs?Successful treatment of high-risk myelodysplastic syndrome with decitabine-based chemotherapy followed by haploidentical lymphocyte infusion: A case report and literature review.Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity.DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancerEpigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
P2860
Q26744500-8D943776-8851-4709-945E-10353D82BA70Q26781191-856EABF2-2750-4E3D-B05F-C7CD2EE04EBFQ26797280-E3F78047-A268-40C0-BD15-4F40AA137C1AQ28066199-7F739B3C-5A91-4820-9D3A-1087D9EFD185Q28076473-5C0D472F-34E3-4F40-8895-CA950721EB6FQ30850591-BFE8524D-BA0D-48BD-A596-53087ED88178Q37437334-049B90AC-622B-4108-A8B2-A87E7948FD10Q37589140-39A3CE07-7273-49CD-83EE-114135AD2AC0Q37724905-DA536FA0-0D3C-4895-BCBC-CD8EEED0FCB1Q38390185-5A3F5E82-D52D-4D57-893A-0612A081B9B1Q38749824-3DDFC4FA-178F-49CA-8662-01B3389533F6Q38779204-73F94DFA-9B92-43B8-8643-3C571F888B7AQ38838643-37DD2847-1AA0-4104-B937-7C6ECD65D3B1Q39130451-5FC2E768-D8E3-4D77-A00E-7B146AE5A16CQ40469741-29A44A07-7DF0-43C0-B3C1-D426A9A703D6Q41078811-131B4395-9B81-4107-8B2D-9FA445453FF7Q41247038-E6EC1413-359B-4396-9DDA-59FF0B513D63Q41573313-50BAA69F-14C4-43A6-9AEF-D8356DF0F59BQ41945124-C0F3933E-C643-4ACB-A026-9C36C3C114EFQ42047687-2B0CA50C-7B58-4364-9942-C927551F72AEQ42106883-15E1AD89-E3D6-447F-9A6A-026AB752A330Q46047154-5510BF0E-961B-40C5-9BD1-2442A44EEB22Q47135020-F181B9E8-D015-45BA-B062-2CA750830E2FQ47595821-845542BA-1F32-401B-8FFD-CFD26815F712Q49537326-1788DB86-9181-417C-8A95-55A4C202E2ECQ52320729-19F3CEA6-AB0B-4020-B521-29C517B7D3DDQ52581847-A530C0D7-F67A-4780-90D9-DC9FE0B9885EQ52597632-E1F75FDB-29F4-4BD5-9EA6-FD4CD17D32F9Q52707883-0F6E3ADC-BF28-4F10-81CB-D092669DF2C0Q53724500-9D0687A8-BCB9-43C9-ACA4-DF25861D4275Q55008806-F040D138-CA2F-49F7-9BA4-F79D8A24628DQ55030400-79CBDC99-2B61-4810-8844-F1218871AB74Q55080752-FBBA40EF-3A16-4F36-AC7D-B7CA1C29AB9AQ55299267-DE1914CB-7BE2-4C89-BAAB-D19F427CA484Q56890318-ED33B091-37A1-4988-9899-10D84D81FF22Q57138927-5E63E6FB-8C7D-4A33-8904-BAE961ADC53E
P2860
Augmenting antitumor immune responses with epigenetic modifying agents.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Augmenting antitumor immune responses with epigenetic modifying agents.
@en
type
label
Augmenting antitumor immune responses with epigenetic modifying agents.
@en
prefLabel
Augmenting antitumor immune responses with epigenetic modifying agents.
@en
P2093
P2860
P356
P1476
Augmenting antitumor immune responses with epigenetic modifying agents.
@en
P2093
Erika Héninger
Joshua M Lang
Timothy E G Krueger
P2860
P356
10.3389/FIMMU.2015.00029
P577
2015-02-04T00:00:00Z